Oncimmune Holdings logo

ONC - Oncimmune Holdings Share Price

133.5p 14.0  11.7%

Last Trade - 05/06/20

Sector
Healthcare
Size
Small Cap
Market Cap £84.8m
Enterprise Value £85.9m
Revenue £358k
Position in Universe 967th / 1817
Bullish
Bearish
Unlock ONC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 30 November 2019, Oncimmune Holdings PLC revenues increased from £121K to £308K. Net loss increased 52% to £5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Administrative expenses increase of 94% to £5.1M (expense), Research and development expenses increase of 46% to £1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ONC Revenue Unlock ONC Revenue

Net Income

ONC Net Income Unlock ONC Revenue

Normalised EPS

ONC Normalised EPS Unlock ONC Revenue

PE Ratio Range

ONC PE Ratio Range Unlock ONC Revenue

Dividend Yield Range

ONC Dividend Yield Range Unlock ONC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONC EPS Forecasts Unlock ONC Revenue
Profile Summary

Oncimmune Holdings Plc is a cancer diagnosis company. The Company is engaged in developing and commercializing its EarlyCDT platform technology. Its geographical segments include United Kingdom, North America and Rest of the world. It is engaged in the development of autoantibody tests that can be applied to a range of solid tumor types. EarlyCDT-Lung is a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. EarlyCDT-Lung test is being used in the randomized trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland Early Childhood Longitudinal Study (ECLS) of over 12,000 high-risk smokers. It is also developing the EarlyCDT tests for other cancers, which include in particular the liver and ovarian cancers. It has sold over 145,000 tests in the United States and the United Kingdom.

Directors
Last Annual May 31st, 2019
Last Interim November 30th, 2019
Incorporated October 9, 2015
Public Since May 18, 2016
No. of Shareholders: n/a
No. of Employees: 76
Sector Healthcare
Industry Healthcare Providers & Services
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 63,500,047
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ONC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ONC
Upcoming Events for ONC
Friday 27th November, 2020 Estimate
Oncimmune Holdings PLC Annual Shareholders Meeting
Frequently Asked Questions for Oncimmune Holdings
What is the Oncimmune Holdings share price?

As of 05/06/20, shares in Oncimmune Holdings are trading at 133.5p, giving the company a market capitalisation of £84.8m. This share price information is delayed by 15 minutes.

How has the Oncimmune Holdings share price performed this year?

Shares in Oncimmune Holdings are currently trading at 133.5p and the price has moved by 44.32% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncimmune Holdings price has moved by 64.81% over the past year.

What are the analyst and broker recommendations for Oncimmune Holdings?

Of the analysts with advisory recommendations for Oncimmune Holdings, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oncimmune Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Oncimmune Holdings next release its financial results?

Oncimmune Holdings is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-11-30
What is the Oncimmune Holdings dividend yield?

Oncimmune Holdings does not currently pay a dividend.

Does Oncimmune Holdings pay a dividend?

Oncimmune Holdings does not currently pay a dividend.

When does Oncimmune Holdings next pay dividends?

Oncimmune Holdings does not currently pay a dividend.

How do I buy Oncimmune Holdings shares?

To buy shares in Oncimmune Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncimmune Holdings?

Shares in Oncimmune Holdings are currently trading at 133.5p, giving the company a market capitalisation of £84.8m.

Where are Oncimmune Holdings shares listed? Where are Oncimmune Holdings shares listed?

Here are the trading details for Oncimmune Holdings:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ONC
What kind of share is Oncimmune Holdings?

Based on an overall assessment of its quality, value and momentum, Oncimmune Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncimmune Holdings share price forecast 2020?

Shares in Oncimmune Holdings are currently priced at 133.5p. At that level they are trading at 12.36% discount to the analyst consensus target price of 152.33.

Analysts covering Oncimmune Holdings currently have a consensus Earnings Per Share (EPS) forecast of -0.109 for the next financial year.

How can I tell whether the Oncimmune Holdings share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncimmune Holdings. Over the past six months, the relative strength of its shares against the market has been 0.232k%. At the current price of 133.5p, shares in Oncimmune Holdings are trading at 0.104k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncimmune Holdings PE Ratio?

We were not able to find PE ratio data for Oncimmune Holdings.

Who are the key directors of Oncimmune Holdings?

Oncimmune Holdings's management team is headed by:

Matthew Hall - CFO
Greg Stanley - CEX
Andrew Stewart - GCN
Geoffrey Hamilton-Fairley - VCH
Adam Hill - CEO
Andrea Murray - OTH
James Jett - OTH
Neal Navani - OTH
Dan Calvo - OTH
Laura Peek - OTH
Meinhard Schmidt - NEC
Carsten Schroeder - NED
Timothy Bunting - NVC
Annalisa Jenkins - NED
Julian Hirst - NED
Who are the major shareholders of Oncimmune Holdings?

Here are the top five shareholders of Oncimmune Holdings based on the size of their shareholding:

Balderton Capital (UK) LLP Venture Capital
Percentage owned: 10.73% (6.81m shares)
Genostics Company, Ltd. Corporation
Percentage owned: 10.09% (6.41m shares)
Sharp (Richard Simon) Individual Investor
Percentage owned: 7.11% (4.52m shares)
LF Ruffer Total Return Fund Mutual Fund
Percentage owned: 5.25% (3.33m shares)
Hamilton-Fairley (Geoffrey Neil) Individual Investor
Percentage owned: 5.1% (3.24m shares)
Similar to ONC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.